Disease or Syndrome
Roche’s Genentech builds autoimmune Repertoire with deal worth up to $765M
Repertoire, genentech, Autoimmune Diseases, Immune Medicines, Partnership
CMS would absorb 340B drug discount program under leaked HHS reorganization proposal
340B, Centers for Medicare and Medicaid Services, HHS, reorganization, Programs – Publication Format, proposal – intent, drug discount program, United States Health Resources and Services Administration, CMS, Policy, Leaked, Changing
Facing added pressure from Eli Lilly, Novo Nordisk submits for FDA approval of oral GLP-1 obesity drug
Nordisk, Obesity, Approved, Oral cavity, Glucagon-Like Peptide 1, Market, Pressure- physical agent, eli lilly, competition, Novo, semaglutide, United States Food and Drug Administration, United States Food and Drug Administration
Dupixent notches seventh disease approval with urticaria nod
Dupixent, Chronic Spontaneous Urticaria, Approved, Urticaria, United States Food and Drug Administration, seventh
Ono Pharmaceutical and Jorna Therapeutics Partner for AI-Driven RNA Editing Therapies
Ono Pharmaceutical, Jorna Therapeutics, AI Drug Discovery, RNA Editing Therapies
FDA rejection of extended dosing interval is another piece of bad news for Regenerons Eylea HD
United States Food and Drug Administration, Interval, Regeneron, dosing, Extension, Eylea HD, rejection, Age related macular degeneration, Diabetic Retinopathy
Lilly’s oral GLP-1 succeeds in first Phase III test, delivering promising weight loss
orforglipron, Glucagon-Like Peptide 1, Weight Loss, Oral cavity, orforglipron, Phase 3 Clinical Trials, Diabetes Mellitus, Non-Insulin-Dependent, Hemoglobin A1c measurement, Safety, Injectables
Leaked HHS budget signals $40B in cuts, assumes ACA subsidies expire
Budgets, HHS, Patient Protection and Affordable Care Act, Subsidies, Agencies, Leaked, Administration occupational activities, proposal – intent, assumes, Programs – Publication Format
FDA clears its first prescription migraine app, from Click Therapeutics
United States Food and Drug Administration, CT-132, Migraine Disorders, Click Therapeutics, click, first
Sanofi pens $1.8B research deal for 2 bispecific antibodies aimed at autoimmune, immunology
Antibodies, Bispecific, Autoimmune, Inflammatory Bowel Diseases, sanofi, Earendil Labs, Immunology, Collaboration, development aspects